Pretreatment method and detection method for measuring concentration of transthyretin (TTR) tetramer in blood
A technology for determination of thyroxine protein and concentration, applied in the field of analysis and detection, can solve the problems of inability to obtain TTR, inability to distinguish the type of TTR tetramer, inability to measure TTR tetramer alone, etc., and achieves short detection time, good specificity, Simple to use effects
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0048] Example 1 Determination of the concentration of transthyretin (TTR) tetramer in 96 cases of plasma samples
[0049] Plasma samples were collected from apparently healthy people aged 20-60 years old collected by Dalian Runsheng Kangtai Medical Laboratory Co., Ltd., including 49 males and 47 females, all of whom had signed informed consent.
[0050] 1 Configuration of calibration solution
[0051] (1) Preparation of calibration working solution: Accurately prepare recombinant wild-type transthyretin (TTR) tetramer stock solution (80 μmol / L), dilute it with PBS (pH 7.4) to obtain an intermediate stock solution, and use interval dilution method Dilute the intermediate stock solution to obtain a series of transthyretin (TTR) tetramer calibration working solutions with a concentration of 1 μmol / L, 2 μmol / L, 5 μmol / L, 10 μmol / L, 20 μmol / L, and 40 μmol / L, for future use.
[0052] (2) Calibration curve solution: Take 50 μL of calf serum (blank matrix), add 50 μL of recombinan...
Embodiment 2
[0081] Example 2 Qualitative identification and concentration determination of transthyretin tetramer in plasma
[0082] A total of four experimental samples were obtained from Dalian Runsheng Kangtai Medical Laboratory Co., Ltd. Among them, there were 3 genetic samples of the D39Y variant family (father and two daughters), of which sample 1 was the father, who had been diagnosed by a local tertiary hospital. Transthyretin amyloid cardiomyopathy (ATTR-CM); sample 2 is the eldest daughter, who was identified as a gene carrier by gene sequencing in a local tertiary hospital; sample 3 is the second daughter, who was identified as a gene carrier by gene sequencing in a local tertiary hospital normal sample. Sample 4 is a patient with T96R mutation, who was identified as a gene carrier by gene sequencing in a local tertiary hospital, and the above four candidates have signed informed consent.
[0083] 1. Configuration of calibration solution
[0084] Except that the recombinant...
PUM
| Property | Measurement | Unit |
|---|---|---|
| diameter | aaaaa | aaaaa |
| molecular weight | aaaaa | aaaaa |
| diameter | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More 


